KRW 5130.0
(-1.35%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 20.73 Billion KRW | -36.64% |
2022 | 32.71 Billion KRW | -40.31% |
2021 | 54.81 Billion KRW | 488.67% |
2020 | 9.31 Billion KRW | -55.87% |
2019 | 21.1 Billion KRW | 136.67% |
2018 | 8.91 Billion KRW | -82.55% |
2017 | 51.08 Billion KRW | 3608.91% |
2016 | 1.37 Billion KRW | -9.35% |
2015 | 1.51 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 10.63 Billion KRW | -31.88% |
2024 Q1 | 15.6 Billion KRW | -24.72% |
2023 Q2 | 27.76 Billion KRW | -25.81% |
2023 FY | 20.73 Billion KRW | -36.64% |
2023 Q4 | 20.73 Billion KRW | -4.76% |
2023 Q3 | 21.76 Billion KRW | -21.59% |
2023 Q1 | 37.41 Billion KRW | 14.36% |
2022 Q2 | 51.97 Billion KRW | -30.1% |
2022 FY | 32.71 Billion KRW | -40.31% |
2022 Q4 | 32.71 Billion KRW | -26.57% |
2022 Q3 | 44.55 Billion KRW | -14.27% |
2022 Q1 | 74.35 Billion KRW | 35.65% |
2021 Q4 | 54.81 Billion KRW | 12.5% |
2021 Q2 | 8.19 Billion KRW | -0.1% |
2021 Q1 | 8.2 Billion KRW | -11.87% |
2021 FY | 54.81 Billion KRW | 488.67% |
2021 Q3 | 48.72 Billion KRW | 494.35% |
2020 Q3 | 7.73 Billion KRW | -84.47% |
2020 Q1 | 18.52 Billion KRW | -5.23% |
2020 FY | 9.31 Billion KRW | -55.87% |
2020 Q2 | 49.77 Billion KRW | 168.66% |
2020 Q4 | 9.31 Billion KRW | 20.45% |
2019 Q3 | 18.59 Billion KRW | 0.0% |
2019 FY | 21.1 Billion KRW | 136.67% |
2019 Q4 | 19.55 Billion KRW | 5.11% |
2019 Q1 | - KRW | -100.0% |
2018 Q4 | 8.91 Billion KRW | 0.0% |
2018 FY | 8.91 Billion KRW | -82.55% |
2017 FY | 51.08 Billion KRW | 3608.91% |
2016 FY | 1.37 Billion KRW | -9.35% |
2015 FY | 1.51 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 27.25 Billion KRW | 23.936% |
InBody Co.,Ltd | 24.62 Billion KRW | 15.796% |
Curexo Inc. | 6.94 Billion KRW | -198.689% |
Seegene, Inc. | 221.05 Billion KRW | 90.621% |
i-SENS, Inc. | 195.32 Billion KRW | 89.386% |
Ray Co., Ltd. | 128.35 Billion KRW | 83.848% |
Gencurix Inc. | 21.49 Billion KRW | 3.565% |
L&C Bio Co., Ltd | 105.37 Billion KRW | 80.325% |